Aspire Biopharma Holdings Inc (ASBP)

$1.02 +0.01 (0.99%)
Market Cap 2.74M
Revenue (ttm) 6,202.00
Net Income (ttm) -12.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.54
Volume 164,600
Avg Vol 847,650
Day's Range N/A - N/A
Shares Out 2.69M
Stochastic %K 56%
Beta 0.99
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 592 7399
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Arnie_510
Arnie_510 Apr. 5 at 3:36 PM
$ASBP Special meeting on April 10 to approve more Reverse Stock Splits.
0 · Reply
Arnie_510
Arnie_510 Apr. 5 at 3:35 PM
$ASBP My guess would be after a 1 for 500 reverse stock split.
0 · Reply
Psikus
Psikus Apr. 4 at 2:10 AM
$ASBP When $100?
1 · Reply
METS1
METS1 Apr. 3 at 4:12 AM
$ASBP THAT'S A FACT
0 · Reply
METS1
METS1 Apr. 3 at 4:10 AM
$ASBP Have a Blessed Easter weekend and thank GOD for what he has given you. For you are Blessed, so help other who need help. You can't take all the money you when you die. If you don't the next stage in you life will be very, very bad for you.
0 · Reply
METS1
METS1 Apr. 3 at 1:51 AM
$ASBP I see some one sold 14 shares and the price went down 2 cents. What a bunch of bull****
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 6:50 PM
$ASBP YOUR CASH IS SAFE HERE! It ain’t goin nowhere, except in their pockets.
2 · Reply
Arnie_510
Arnie_510 Apr. 2 at 6:46 PM
$ASBP This reminds me of a Roach Motel Where your cash checks in but it don’t check out.
1 · Reply
Arnie_510
Arnie_510 Apr. 2 at 6:22 PM
$ASBP Things could not be better 🤣 There’s nothing better than a 1 for 500 reverse stock split!
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 5:57 PM
$ASBP Wow I never thought Moon and I would become friends.
1 · Reply
Latest News on ASBP
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 19, 2026, 8:00 AM EDT - 17 days ago

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 17, 2026, 8:30 AM EDT - 19 days ago

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Mar 12, 2026, 8:00 AM EDT - 24 days ago

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Mar 10, 2026, 8:30 AM EDT - 26 days ago

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Mar 3, 2026, 8:00 AM EST - 4 weeks ago

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 25, 2026, 8:30 AM EST - 5 weeks ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 20, 2026, 8:00 AM EST - 6 weeks ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 19, 2026, 8:00 AM EST - 6 weeks ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 17, 2026, 8:30 AM EST - 6 weeks ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 13, 2026, 8:00 AM EST - 7 weeks ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 12, 2026, 8:00 AM EST - 7 weeks ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 11, 2026, 7:45 AM EST - 7 weeks ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2026, 8:00 AM EST - 7 weeks ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 5, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Feb 3, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 29, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 27, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 22, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 21, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 20, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Jan 14, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Jan 7, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 3 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 4 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 4 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 4 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 4 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 5 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 6 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Oct 2, 2025, 2:44 PM EDT - 6 months ago

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 6 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 8 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 8 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 22, 2025, 10:45 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jul 9, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 24, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Jun 10, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 8, 2025, 8:00 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Apr 14, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Arnie_510
Arnie_510 Apr. 5 at 3:36 PM
$ASBP Special meeting on April 10 to approve more Reverse Stock Splits.
0 · Reply
Arnie_510
Arnie_510 Apr. 5 at 3:35 PM
$ASBP My guess would be after a 1 for 500 reverse stock split.
0 · Reply
Psikus
Psikus Apr. 4 at 2:10 AM
$ASBP When $100?
1 · Reply
METS1
METS1 Apr. 3 at 4:12 AM
$ASBP THAT'S A FACT
0 · Reply
METS1
METS1 Apr. 3 at 4:10 AM
$ASBP Have a Blessed Easter weekend and thank GOD for what he has given you. For you are Blessed, so help other who need help. You can't take all the money you when you die. If you don't the next stage in you life will be very, very bad for you.
0 · Reply
METS1
METS1 Apr. 3 at 1:51 AM
$ASBP I see some one sold 14 shares and the price went down 2 cents. What a bunch of bull****
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 6:50 PM
$ASBP YOUR CASH IS SAFE HERE! It ain’t goin nowhere, except in their pockets.
2 · Reply
Arnie_510
Arnie_510 Apr. 2 at 6:46 PM
$ASBP This reminds me of a Roach Motel Where your cash checks in but it don’t check out.
1 · Reply
Arnie_510
Arnie_510 Apr. 2 at 6:22 PM
$ASBP Things could not be better 🤣 There’s nothing better than a 1 for 500 reverse stock split!
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 5:57 PM
$ASBP Wow I never thought Moon and I would become friends.
1 · Reply
Psilocyb
Psilocyb Apr. 2 at 5:39 PM
$ASBP low volume😴
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 2:51 PM
$ASBP Some character showed up to my place in a black Ninja 🥷 outfit doing backflips and summer salts swinging a sword. (Reminded me of Dr Moon) I asked him if he was here to trim my shrubs and bushes but he started speaking in Chinese and ran off.
3 · Reply
Arnie_510
Arnie_510 Apr. 2 at 2:41 PM
$ASBP It seems @DRWenMoonPHD has had a change of heart. He sounds pretty hostile all of a sudden.
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 2:07 PM
$ASBP 𝗥𝗲𝘃𝗲𝗿𝘀𝗲 𝗦𝘁𝗼𝗰𝗸 𝗦𝗽𝗹𝗶𝘁𝘀 “𝗥” 𝗨𝘀 🦒 These people hate my guts, they never counted on me showing up to their party. 1 for 40 reverse split recently enacted and now this.
0 · Reply
Bearfaith
Bearfaith Apr. 2 at 9:53 AM
$ASBP you know, the funny thing is, the stock would never reach $1 with the volume in the millions, but it somehow reaches $1 with volume in the thousands…,
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 2:30 AM
$ASBP You guys are funny! DrWenGoon and friends unblock and reblock me, unblock and reblock me. WTF are you 🤡 ’s trying to hide?
0 · Reply
Arnie_510
Arnie_510 Apr. 2 at 12:04 AM
$ASBP
0 · Reply
Arnie_510
Arnie_510 Apr. 1 at 11:55 PM
$ASBP
0 · Reply
Arnie_510
Arnie_510 Apr. 1 at 11:53 PM
$ASBP These people hate my guts.
0 · Reply
Arnie_510
Arnie_510 Apr. 1 at 10:53 PM
$ASBP All hope is not lost. If their trials fail they can always proceed with the 1 for 500 reverse stock split and issue themselves more shares. It’s a win win for them! Your money will always be in safe hands!
0 · Reply
Arnie_510
Arnie_510 Apr. 1 at 10:48 PM
$ASBP I see they created some more bagholders today. I’d even be willing to bet everyone got a chance in the cash booth.
0 · Reply
Bearfaith
Bearfaith Apr. 1 at 8:43 PM
$ASBP received the final report in September 2025. The results of the clinical trials were positive, demonstrating that Aspire’s sublingual delivery technology results in much faster aspirin bioavailability in the blood (compared to aspirin tablets) and that the anti-coagulant property of aspirin occurs much quicker with Aspire’s product. These results will be the backbone of a 505(b)(2) submission to the FDA planned for late 2026.
0 · Reply